Aclaris Therapeutics’ (ACRS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a report published on Thursday,Benzinga reports. HC Wainwright currently has a $16.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.55) EPS.

Other analysts also recently issued research reports about the company. Craig Hallum started coverage on Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price objective on the stock. Wall Street Zen lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.80.

Aclaris Therapeutics Price Performance

Shares of Aclaris Therapeutics stock opened at $3.74 on Thursday. Aclaris Therapeutics has a 1-year low of $1.05 and a 1-year high of $4.89. The company has a market capitalization of $451.04 million, a P/E ratio of -7.06 and a beta of 0.88. The business’s fifty day moving average price is $3.39 and its two-hundred day moving average price is $2.76.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). The business had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.07 million. Aclaris Therapeutics had a negative net margin of 829.58% and a negative return on equity of 52.04%. On average, research analysts expect that Aclaris Therapeutics will post -0.82 earnings per share for the current fiscal year.

Institutional Trading of Aclaris Therapeutics

A number of institutional investors have recently bought and sold shares of the company. Millennium Management LLC lifted its holdings in shares of Aclaris Therapeutics by 111.0% during the 1st quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company’s stock valued at $6,325,000 after buying an additional 2,175,101 shares during the last quarter. Geode Capital Management LLC lifted its stake in Aclaris Therapeutics by 108.4% in the second quarter. Geode Capital Management LLC now owns 2,464,779 shares of the biotechnology company’s stock valued at $3,501,000 after acquiring an additional 1,282,042 shares during the last quarter. Kotler Kevin bought a new stake in Aclaris Therapeutics in the fourth quarter worth approximately $5,135,000. Palo Alto Investors LP increased its stake in shares of Aclaris Therapeutics by 12.7% during the 3rd quarter. Palo Alto Investors LP now owns 1,566,840 shares of the biotechnology company’s stock worth $2,977,000 after purchasing an additional 176,812 shares during the last quarter. Finally, State Street Corp lifted its stake in shares of Aclaris Therapeutics by 35.3% in the 4th quarter. State Street Corp now owns 1,506,403 shares of the biotechnology company’s stock valued at $4,534,000 after purchasing an additional 393,257 shares during the last quarter. Institutional investors and hedge funds own 98.34% of the company’s stock.

Key Headlines Impacting Aclaris Therapeutics

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: HC Wainwright reaffirmed a “Buy” rating and kept a $16.00 price target on ACRS — implying large upside from current levels; this analyst support and high target is bullish for investor sentiment and can attract buyers. HC Wainwright Reaffirms Buy
• Positive Sentiment: Aclaris completed patient enrollment in its randomized Phase 2 trial of bosakitug (ATI-045) for moderate-to-severe atopic dermatitis (109 patients); topline results are expected in Q4 2026 — this advances a key clinical program and provides a clear near-term binary catalyst. Enrollment Completed — GlobeNewswire
• Positive Sentiment: Analyst model tweak: HC Wainwright slightly raised its FY2026 EPS estimate for Aclaris (less negative), reflecting improved visibility into development milestones — small fundamental upgrade that supports the buy rating and target.
• Neutral Sentiment: Market consensus and analyst coverage remain modestly positive overall (consensus “Moderate Buy”); separate notes outline FY2027 earnings expectations — useful for longer-term valuation but not immediate price drivers. Analyst Consensus — AmericanBankingNews
• Neutral Sentiment: Short-interest reports in the recent feed are internally inconsistent (showing zero shares and NaN changes); there’s no clear evidence of a material short-squeeze or large short buildup impacting the stock today.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.